John G. Connolly

Harvard Pilgrim Healthcare Institute

Poster(s):

• (A-350) Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results From an Interim Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-333) Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-334) Incidence rates of safety outcomes in a post-approval study of the Pfizer-BioNTech monovalent COVID-19 vaccine in the United States, booster dose analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-315) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors, Sodium Glucose Cotransporter 2 Inhibitors, or Sulfonylurea in the U.S. Food and Drug Administration’s Sentinel System
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (C-077) Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (B-091) Utilization of Type 2 Diabetes Mellitus Products in the Sentinel Distributed Database, 2008-2024
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET